Literature DB >> 17345108

3D-QSAR studies of substituted 1-(3, 3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists.

Yogesh D Aher1, Avantika Agrawal, Prasad V Bharatam, Prabha Garg.   

Abstract

3D-QSAR studies on the derivatives of 1-(3,3-diphenylpropyl)-piperidinyl amide and urea as CCR5 receptor antagonists were performed by comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA) methods to rationalize the structural requirements responsible for the inhibitory activity of these compounds. The global minimum energy conformer of the template molecule, the most active and pharmacokinetically stable molecule of the series, was obtained by systematic search and used to build structures of the molecules in the dataset. The best predictions for the CCR5-receptor were obtained with the CoMFA standard model (q (2) = 0.787, r (2) = 0.962) and CoMSIA model combined steric, electrostatic and hydrophobic fields (q (2) = 0.809, r (2) = 0.951). The predictive ability of CoMFA and CoMSIA were determined using a test set of 12 compounds giving predictive correlation coefficients of 0.855 and 0.83, respectively, indicating good predictive power. Further, the robustness of the model was verified by bootstrapping analysis. The contour maps produced by the CoMFA and CoMSIA models were used to identify the structural features relevant to the biological activity in this series. Based on the CoMFA and CoMSIA analysis, we have identified some key features in the series that are responsible for CCR5 antagonistic activity which may be used to design more potent 1-(3,3-diphenylpropyl)-piperidinyl derivatives and predict their activity prior to synthesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17345108     DOI: 10.1007/s00894-007-0173-z

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  24 in total

1.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

Authors:  C P Dorn; P E Finke; B Oates; R J Budhu; S G Mills; M MacCoss; L Malkowitz; M S Springer; B L Daugherty; S L Gould; J A DeMartino; S J Siciliano; A Carella; G Carver; K Holmes; R Danzeisen; D Hazuda; J Kessler; J Lineberger; M Miller; W A Schleif; E A Emini
Journal:  Bioorg Med Chem Lett       Date:  2001-01-22       Impact factor: 2.823

2.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

Authors:  D Kim; L Wang; C G Caldwell; P Chen; P E Finke; B Oates; M MacCoss; S G Mills; L Malkowitz; S L Gould; J A DeMartino; M S Springer; D Hazuda; M Miller; J Kessler; R Danzeisen; G Carver; A Carella; K Holmes; J Lineberger; W A Schleif; E A Emini
Journal:  Bioorg Med Chem Lett       Date:  2001-12-17       Impact factor: 2.823

Review 4.  New targets for inhibitors of HIV-1 replication.

Authors:  J P Moore; M Stevenson
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

5.  Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.

Authors:  Yong Xu; Hong Liu; Chunying Niu; Cheng Luo; Xiaomin Luo; Jianhua Shen; Kaixian Chen; Hualiang Jiang
Journal:  Bioorg Med Chem       Date:  2004-12-01       Impact factor: 3.641

Review 6.  Chemokine receptors - the new frontier for AIDS research.

Authors:  T N Wells; A E Proudfoot; C A Power; M Marsh
Journal:  Chem Biol       Date:  1996-08

Review 7.  HIV chemotherapy.

Authors:  D D Richman
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

8.  Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Authors:  W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

9.  Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.

Authors:  Jeremy N Burrows; John G Cumming; Shaun M Fillery; Gordon A Hamlin; Julian A Hudson; Ruth J Jackson; Sharon McLaughlin; John S Shaw
Journal:  Bioorg Med Chem Lett       Date:  2005-01-03       Impact factor: 2.823

10.  Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41.

Authors:  Rogier W Sanders; Martijn M Dankers; Els Busser; Michael Caffrey; John P Moore; Ben Berkhout
Journal:  Retrovirology       Date:  2004-03-09       Impact factor: 4.602

View more
  6 in total

1.  A combined LS-SVM & MLR QSAR workflow for predicting the inhibition of CXCR3 receptor by quinazolinone analogs.

Authors:  Antreas Afantitis; Georgia Melagraki; Haralambos Sarimveis; Panayiotis A Koutentis; Olga Igglessi-Markopoulou; George Kollias
Journal:  Mol Divers       Date:  2009-05-30       Impact factor: 2.943

2.  www.3d-qsar.com: a web portal that brings 3-D QSAR to all electronic devices-the Py-CoMFA web application as tool to build models from pre-aligned datasets.

Authors:  Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2019-10-08       Impact factor: 3.686

3.  Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.

Authors:  Yong Ai; Shao-Teng Wang; Ping-Hua Sun; Fa-Jun Song
Journal:  Int J Mol Sci       Date:  2010-09-28       Impact factor: 5.923

Review 4.  Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.

Authors:  Jian J Tan; Xiao J Cong; Li M Hu; Cun X Wang; Lee Jia; Xing-Jie Liang
Journal:  Drug Discov Today       Date:  2010-01-22       Impact factor: 7.851

5.  QSAR models for CXCR2 receptor antagonists based on the genetic algorithm for data preprocessing prior to application of the PLS linear regression method and design of the new compounds using in silico virtual screening.

Authors:  Tahereh Asadollahi; Shayessteh Dadfarnia; Ali Mohammad Haji Shabani; Jahan B Ghasemi; Maryam Sarkhosh
Journal:  Molecules       Date:  2011-02-25       Impact factor: 4.411

6.  Molecular modeling studies on 11H-dibenz[b,e]azepine and dibenz[b,f][1,4]oxazepine derivatives as potent agonists of the human TRPA1 receptor.

Authors:  Yong Ai; Fa-Jun Song; Shao-Teng Wang; Qiang Sun; Ping-Hua Sun
Journal:  Molecules       Date:  2010-12-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.